<DOC>
	<DOCNO>NCT01862718</DOCNO>
	<brief_summary>Background : Pilot study assess feasibility combine treatment modality synergistic ( radiation thermal ablation ) . Thermal ablation Radiofrequency Ablation ( RFA ) microwave ablation ( MWA ) standard treatment focal neoplasm liver . High volume scatter location tumor burden result inability successfully use technology large proportion patient hepatic neoplasm . Methods enhance treatment volume could advantageous potentially increase indication thermal ablation number patient benefit local ablation . Primary objective : To determine safety combine 2 standard therapy ( thermal ablation external beam radiation therapy ) liver neoplasm 10 cm diameter . Eligibility : Patients great 18 year age pathologically proven unresectable primary metastatic hepatic neoplasm Patients whose extent hepatic metastasis represent approximately less 60 % total liver volume AND whose extrahepatic metastatic disease determine minimal ECOG performance status less equal 2 life expectancy 3 month Patients history chemotherapy , radiation therapy , biological therapy least 4 week prior start study treatment , 4 week treatment Patients must acute , critical illness If clinical image evidence cirrhosis present , Bilirubin must less 3 mg/dl Child-Pugh Classification A , ( Class B &amp; C exclude ) Design : Patients undergo external beam radiation well thermal ablation accord standard operating procedure NCI NIH CC . Patients monitor use standard image study clinically warrant . Patients may treat second ( ) thermal ablation procedure ALONE deem beneficial patient investigator . The sample size 10 evaluable patient</brief_summary>
	<brief_title>Fusion Guided Thermal Ablation Combined With External Beam Radiation Hepatic Neoplasms</brief_title>
	<detailed_description>Background : Pilot study assess feasibility combine treatment modality synergistic ( radiation thermal ablation ) . Thermal ablation Radiofrequency Ablation ( RFA ) microwave ablation ( MWA ) standard treatment focal neoplasm liver . High volume scatter location tumor burden result inability successfully use technology large proportion patient hepatic neoplasm . Methods enhance treatment volume could advantageous potentially increase indication thermal ablation number patient benefit local ablation . Primary objective : To determine safety combine 2 standard therapy ( thermal ablation external beam radiation therapy ) liver neoplasm 10 cm diameter . Eligibility : Patients great 18 year age pathologically proven unresectable primary metastatic hepatic neoplasm Patients whose extent hepatic neoplasm represent approximately less 60 % total liver volume AND whose extrahepatic metastatic disease determine minimal ECOG performance status less equal 2 life expectancy 3 month Patients history chemotherapy , radiation therapy liver , biological therapy must last dose/ treatment least 14 day prior start study treatment . Patients must acute , critical illness Design : Patients undergo external beam radiation well thermal ablation accord standard operating procedure NCI NIH CC . Patients monitor use standard image study clinically warrant . Patients may treat second ( ) thermal ablation procedure ALONE deem beneficial patient investigator . The sample size 10 evaluable patient</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients hepaticdominant neoplasms life limit component disease hepatic neoplasms Patients hepatic lesion must consider technically unresectable overall health make surgery inadvisable Have 5 few lesion single lesion great 10 cm maximum diameter Patients extrahepatic neoplasm unresected primary lesion consider eligible extrahepatic disease minimal stable Serum Creatinine le 2.0 mg/dl unless measure creatinine clearance great 60 ml/min . Absolute neutrophil count ( ANC ) great equal to1500/m3 without help Filgastrim , hemoglobin great 8 g/dL , platelet count great equal 75,000 m3 Bilirubin le 3 mg/dl , AST ALT le 5 X upper limit normal except presence obstructive liver neoplasm ALT/AST may 10 X upper limit normal . Prothrombin Time ( PT ) within 2 second upper limit normal ( INR less 1.8 ) Extent hepatic neoplasm approximately less 60 % total hepatic volume Patients must pathology proof neoplasm . If proof pathology unavailable , histopathological confirmation liver neoplasm may requisite set clinical radiological characteristic highly suggestive neoplastic diagnosis , designation determine PI medical surgical oncologist , NCI multidisciplinary gastrointestinal tumor board review , event absence consensus . Patients refer ablation radiation liver neoplasm ECOG performance status less equal 2 Life expectancy great 3 month At least 18 year age Age le 85 year Patients must chemotherapy , radiotherapy , biologic therapy malignancy least 28 day prior treatment must recover clinically significant side effect therapeutic diagnostic intervention . EXCLUSION CRITERIA : Portal Vein Occlusion contraindication thermal ablation radiation Prior selective internal radiation therapy ( SIRT ) Yttrium90 prior radiation liver Prior biliary diversion surgery Patients require ongoing chronic anticoagulation eligible . Standard clinical screening procedure perform , clinically lowrisk , patient take aspirin NSAIDS week prior RFA , per clinical standard . Patients active bacterial infection systemic manifestation ( malaise , fever , leukocytosis ) eligible completion appropriate therapy . Any exclusion criterion radiation ablation , ataxia telangiectasia , active connective tissue disease , inflammatory bowel disease , know condition predispose radiation toxicity Patients acute , critical illness Pregnant woman exclude study . Patients exclude pregnancy test childbearing age 55 year old , documented history infertility acquire congenital disorder incompatible pregnancy patient hysterectomy bilateral oophorectomy . Patients also exclude pregnancy test least 50 year age AND menstruate least 12 month OR document Follicle Stimulating Hormone ( FSH ) level great 40 mIU/mL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>December 14, 2016</verification_date>
	<keyword>Fusion</keyword>
	<keyword>Tracking</keyword>
	<keyword>Ablation</keyword>
	<keyword>Hepatic Neoplasms</keyword>
</DOC>